Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114455 | 0.82 | SLC6A3 (0.53) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6040421 | 0.80 | CYP3A4 (0.48) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL17455345 | 0.78 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL20052866 | 0.78 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL17472323 | 0.78 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL1892118 | 0.78 | CYP3A4 (0.48) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL20710609 | 0.78 | CYP3A4 (0.48) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL5999697 | 0.76 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL20604406 | 0.74 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL20604354 | 0.74 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854870-B1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7235658-B2 | Imidazol derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060122207-A1 | Imidazol derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. | 2006-06-08 | — | — | US | disclosed |
| US-7026336-B1 | 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-04-11 | — | — | US | disclosed |
| US-6987119-B2 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-17 | — | — | US | disclosed |
| EP-1261602-B1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1263753-B1 | IMIDAZOL DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030153588-A1 | Imidazol derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-14 | — | — | US | disclosed |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | GAIBA ALESSANDRA (GB) | 2003-07-17 | — | — | US | disclosed |
| EP-1263753-A1 | IMIDAZOL DERIVATIVES AS RAF KINASE INHIBITORS | SmithKline Beecham plc (GB) | 2002-12-11 | — | — | EP | disclosed |
| EP-1261602-A1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-12-04 | — | — | EP | disclosed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001066539-A1 | IMIDAZOL DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066540-A1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | disclosed |
| US-6083949-A | FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR | MERCK & CO., INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5717100-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153588-A1 | Imidazol derivatives as raf kinase inhibitors | RAF1, BRAF, ARAF | SLC6A2 4393/4885SLC6A4 4473/4885SLC6A3 3621/4885 |
| US-20060122207-A1 | Imidazol derivatives as Raf kinase inhibitors | RAF1, BRAF, ARAF | SLC6A2 3581/4885SLC6A4 3626/4885SLC6A3 2276/4885 |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | SLC6A2 4337/4885SLC6A4 4125/4885SLC6A3 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.